Literature DB >> 8943273

Rate-determining steps in HIV-1 protease catalysis. The hydrolysis of the most specific substrate.

Z Szeltner1, L Polgár.   

Abstract

The human immunodeficiency virus type-1 (HIV-1) encodes a protease which is essential for the production of infectious virus. The protease prefers substrates that contain glutamic acid or glutamine at the P2' position. The catalytic role of these residues has been studied by using a highly specific fluorogen substrate, 2-aminobenzoyl-Thr-Ile-Nle-Phe(NO2)-Gln-Arg (substrate QR), and its counterpart (substrate ER) containing Glu in place of Gln. The newly designed substrate ER that contains a pair of charged residues at P2' and P3' sites is the most specific substrate described so far for HIV-1 protease. The specificity rate constant (kcat/Km = 2.1 x 10(7) M-1 s-1) approaches, but does not reach, the diffusion limit. This follows from the appreciable solvent kinetic deuterium isotope effects on the rate constants, indicating that, independent of the salt concentration, the rate-limiting step of the catalysis is a chemical process rather than a physical one. The reaction also has positive entropy of activation. On the other hand, the rate-limiting step for substrate QR changes with increasing salt concentration from a physical to chemical step, while the negative activation entropy becomes positive. The rate increase with substrate ER is 50-fold with respect to substrate QR in the presence of 0.1 M NaCl and diminishes to 3.5-fold at 2.0 M NaCl concentration, as a consequence of a considerable rate increase at high salt concentration with substrate QR but not with substrate ER. The Km value is much lower for the substrate ER (0.8 microM) than for substrate QR (15 microM), indicating a more effective binding for substrate ER at 0.1 M NaCl. Unexpectedly, the strong binding appears to be achieved by the unionized form of Glu in P2', as follows from the remarkably different pH-rate profiles for substrates QR and ER. The effective binding elicited by the glutamic acid may be utilized in designing inhibitors for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943273     DOI: 10.1074/jbc.271.50.32180

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Transition states of native and drug-resistant HIV-1 protease are the same.

Authors:  D Randal Kipp; Jennifer S Hirschi; Aya Wakata; Harris Goldstein; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

2.  Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model.

Authors:  Chia-En Chang; Tongye Shen; Joanna Trylska; Valentina Tozzini; J Andrew McCammon
Journal:  Biophys J       Date:  2006-03-13       Impact factor: 4.033

3.  Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors.

Authors:  Erik C B Johnson; Enrico Malito; Yuequan Shen; Brad Pentelute; Dan Rich; Jan Florián; Wei-Jen Tang; Stephen B H Kent
Journal:  J Mol Biol       Date:  2007-08-02       Impact factor: 5.469

4.  Dynamic and Electrostatic Effects on the Reaction Catalyzed by HIV-1 Protease.

Authors:  Agnieszka Krzemińska; Vicent Moliner; Katarzyna Świderek
Journal:  J Am Chem Soc       Date:  2016-12-09       Impact factor: 15.419

5.  A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease.

Authors:  Ian W Windsor; Ronald T Raines
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-06-27       Impact factor: 7.652

6.  Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability.

Authors:  Hirotaka Ode; Masaru Yokoyama; Tadahito Kanda; Hironori Sato
Journal:  J Mol Model       Date:  2010-05-18       Impact factor: 1.810

7.  HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.

Authors:  Marc Potempa; Sook-Kyung Lee; Nese Kurt Yilmaz; Ellen A Nalivaika; Amy Rogers; Ean Spielvogel; Charles W Carter; Celia A Schiffer; Ronald Swanstrom
Journal:  J Mol Biol       Date:  2018-11-07       Impact factor: 5.469

8.  Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.

Authors:  Stefano Piana; Paolo Carloni; Ursula Rothlisberger
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

9.  A look inside HIV resistance through retroviral protease interaction maps.

Authors:  Aleksejs Kontijevskis; Peteris Prusis; Ramona Petrovska; Sviatlana Yahorava; Felikss Mutulis; Ilze Mutule; Jan Komorowski; Jarl E S Wikberg
Journal:  PLoS Comput Biol       Date:  2007-01-24       Impact factor: 4.475

10.  Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease.

Authors:  Yong Wang; Tamaria G Dewdney; Zhigang Liu; Samuel J Reiter; Joseph S Brunzelle; Iulia A Kovari; Ladislau C Kovari
Journal:  Biology (Basel)       Date:  2012-05-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.